Patent ID: 9737565
Date: 2017-08-22
CPC Classifications: A61K,A61N,A61P

Claim:
1. A composition comprising: a metal-binding glycoprotein; and a chemotherapeutic compound having a formula selected from the group consisting of: a) formula (I) including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: M at each occurrence is independently selected from the group consisting of osmium, ruthenium an rhodium; X is selected from the group consisting of Cl n=1, 2, 3, 4, or 5; q is independently at each occurrence 0, 1, or 2; y is independently at each occurrence 0, 1, or 2; z is independently at each occurrence 1, 2, or 3; Lig Lig Lig R u is an integer; R R R R R R R R b) formula (VI), including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof wherein; M A t is an integer; c) formula (VIIa) including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof wherein: A Lig Lig R u is an integer; R R R R R R R R p is independently at each occurrence 0, 1, or 2; q is independently at each occurrence 0, 1, or 2; and n is 0, 1, 2, 3, 4, or 5; and d) formula (II) including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein; M is selected from the group consisting of manganese, molybdenum, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, platinum, and copper; X is selected from the group consisting of Cl n=0, 1, 2, 3, 4, or 5; y=1, 2, or 3; z=0, 1, or 2; Lig at each occurrence is independently selected from the group consisting of R u is an integer; R R R R R R R R wherein the composition has at least one of the following enhanced properties relative to the chemotherapeutic compound without the glycoprotein: (a) increased uptake by cancer cells; (b) increased uptake by tumors; (c) increased efficacy at wavelengths longer than 600 nm; (d) increased efficacy at wavelengths less than or equal to 600 nm; (e) improved absorbance at wavelengths longer than 600 nm; (f) improved absorbance at wavelengths less than or equal to 600 nm; (g) increased production of reactive oxygen species; (h) increased photodynamic therapy effect under non-hypoxic conditions; (i) increased photodynamic therapy effect under hypoxic conditions; (j) increased LD50; (k) increased MTD; (l) increased photostability; and (m) increased shelf-life.